Retinopathy of Prematurity Clinical Trial
Official title:
Telemedicine Approaches to Evaluating Acute-phase ROP
The primary objective of this multi-center clinical study is to evaluate the validity,
reliability, feasibility, safety and relative cost-effectiveness of a retinopathy of
prematurity (ROP) telemedicine evaluation system to detect eyes of at-risk babies who meet
referral warranted ROP (RW-ROP) criteria and therefore need a diagnostic evaluation by an
ophthalmologist experienced in ROP.
We shall:
1. Calculate the accuracy, using sensitivity and specificity, of the system to provide
remote evaluations when compared with the findings of a "gold standard" indirect
ophthalmoscopic examination performed by a Study-certified ophthalmologist, rigorously
trained in ROP diagnostic examinations (validity);
2. Determine intra-reader and inter-reader agreement for deciding whether digital images
indicate that the eyes of a baby are in need of diagnostic indirect ophthalmoscopy by
an ophthalmologist experienced in ROP (reliability);
3. Determine whether imaging evaluation can be achieved for each baby (feasibility);
4. Examine ocular and systemic complications associated with digital imaging and compared
with those associated with diagnostic examinations performed by an ophthalmologist
(safety);
5. Compare the costs and benefits of adopting a telemedicine retinal imaging system
compared to the current cost of indirect ophthalmoscopic examinations
(cost-effectiveness).
Eligibility Criteria:
• Babies with birth weights of <1251 grams(g) at selected large clinical centers in the US
and Canada.
Procedures:
• Participants will undergo both digital retinal imaging and clinically indicated indirect
ophthalmoscopic examinations on the same day. Wide-field digital images (WF-DI) of both eyes
will be captured by non-physician Certified ROP Imagers (CRIs) using standardized imaging
protocols. The RetCam Shuttle® (Clarity Medical Systems, Pleasanton, CA), a corneal-contact
camera that captures wide field (130 degree field of view) retinal images, will be used.
Masking:
• Study-certified Ophthalmologist and Study-certified Imager at the clinical sites will be
masked to each other's findings. The Study Clinical Coordinator (SCC) will remain unmasked.
SCC will monitor the clinical noteworthy events and report all adverse events to the site
Institutional Review Board (IRB), the Project Director at the Office of Study Chair, and to
the Data Coordinating Center (DCC). DCC will prepare closed-session Data Monitoring and
Oversight Committee (DMOC) reports. The PI at each site will monitor adverse events.
Outcome Measures:
• The primary outcome measure is detection of referral warranted ROP (RW-ROP) on digital
images. Retinal images will be graded by Trained Readers using a standardized protocol to
identify eyes with RW-ROP. Results of the gradings will be compared to the diagnostic
examinations being performed on each child at the same session when images taken. For
comparison, images will also be graded by ROP experts (Expert Readers).
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05043077 -
Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening
|
Phase 4 | |
| Completed |
NCT04838665 -
Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study
|
Phase 4 | |
| Completed |
NCT04408807 -
Stress Induced by Screening for Retinopathy of Prematurity - Should Speculum and Indentation Rather be Avoided
|
N/A | |
| Recruiting |
NCT03083431 -
Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity
|
Phase 2 | |
| Enrolling by invitation |
NCT04985448 -
Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data
|
||
| Recruiting |
NCT02090322 -
Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1
|
N/A | |
| Completed |
NCT00872664 -
Skin and Serum Carotenoids in Preterm Infants Fed on a Formula Supplemented With Carotenoids
|
N/A | |
| Unknown status |
NCT00254176 -
Cysteine Supplementation in Critically Ill Neonates
|
Phase 2/Phase 3 | |
| Completed |
NCT06452524 -
Prematurity and Ophthalmological Changes
|
||
| Completed |
NCT04101721 -
Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity
|
Phase 3 | |
| Enrolling by invitation |
NCT02050971 -
Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates
|
Phase 1 | |
| Terminated |
NCT01335113 -
A Scan Ultrasonography in the Evaluation of Retinopathy of Prematurity
|
||
| Active, not recruiting |
NCT00027222 -
The Early Treatment for Retinopathy of Prematurity Study (ETROP)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06109285 -
Validation of i-ROP DL to Detect More Than Mild ROP
|
N/A | |
| Completed |
NCT01861470 -
REDEXAM - Reducing Painful Eye Examinations in Preterm Infants
|
N/A | |
| Completed |
NCT02014454 -
Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of Premature
|
Phase 2 | |
| Terminated |
NCT00634972 -
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
|
Phase 4 | |
| Completed |
NCT05701124 -
Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity
|
Phase 3 | |
| Completed |
NCT04092127 -
Pain of Premature Babies and RetCam (DOLICAM)
|
||
| Completed |
NCT04621136 -
PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity
|
Phase 1/Phase 2 |